Promoted Content
Promoted Content

Find Novel Immunology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PT001

            Therapeutic Area: Immunology Product Name: PT001

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $180.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration February 03, 2021

            Details:

            Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.

            Slate Bio

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IL233

            Therapeutic Area: Immunology Product Name: IL233

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Epidarex Capital

            Deal Size: $1.7 million Upfront Cash: Undisclosed

            Deal Type: Financing January 19, 2021

            Details:

            Financing will support development of novel IL-2 treatments for various diseases. IL233, Slate's lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases.